Article

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma

2025-12-30

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Glioblastoma (GBM) represents an aggressive malignancy with limited therapeutic options. The immunosuppressive nature of GBM may be reversible with immune checkpoint inhibitor (ICI) treatment, however, initial studies have yet to demonstrate this. It is postulated that trafficking of peripherally activated lymphocytes may play a role in generating a robust intracranial immun...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5a8901b7-659f-5209-8368-060d8c462bb9
DOI: 10.64898/2025.12.23.25342908

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaDOI 10.64898/2025.12.23.25342908Read

Dual checkpoint blockade of glioblastoma with Anti-PD-1 and Anti-LAG-3 promotes expansion of tumor-reactive T cell clones along a unique pathway of differentiationSemantic proximity Read

Immune phenotypes predict survival in patients with glioblastoma multiformeSemantic proximity Read

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Semantic proximity Read

Humanized glioblastoma patient-derived orthotopic xenografts recreate a locally immunosuppressed human immune ecosystem amenable to immunotherapeutic modulationSemantic proximity Read

TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trialsSemantic proximity Read

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read

Immune monitoring using the predictive power of immune profilesSemantic proximity Read

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.Semantic proximity Read

Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma.Semantic proximity Read

Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts.Semantic proximity Read

Association of Blood Biomarkers and Autoimmunity with Immune Related Adverse Events in Patients with Cancer treated with Immune Checkpoint InhibitorsSemantic proximity Read

Polyclonal expansion of functional tumor-reactive lymphocyte infiltrating glioblastoma for personalized cell therapySemantic proximity Read